Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs

Postgraduate Medicine

Volumn 122, Issue 1, 2010, Pages 144-152

  LaSalle, James R ^a  

^a Medical Arts Centers Inc   (United States)

Author keywords

DPP 4 inhibitors; Glucose control; HbA1c; Saxagliptin; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SULFONYLUREA; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA DERIVATIVE;

ARTHRALGIA; BACKACHE; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ALGORITHM; BLOOD; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA;

ADAMANTANE; ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 76349091352     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.01.2108     Document Type: Review

References (43)

1. Resnick HE, Foster GL, Bardsley J, Ratnar RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29(3):531-537.
2. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22(3):403-408.
3. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2008;58:773-795.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
5. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163(11):1306-1316.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
7. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
8. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
9. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel of type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
10. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32(suppl 1):S1-S201.
11. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb/Wilmington, DE: AstraZeneca; 2009.
12. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2007.
13. Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48(15):5025-5037.
14. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376-386.
15. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs. 2008;13(4):593-607.
16. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008;5(2):73-94.
17. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2007;14(2):98-107.
18. DeFronzo R, Hissa M, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649-1655.
19. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611 622.
20. Hollander P, Li J, Allen E, Chen R; CV181-013 investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810-4819.
21. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
22. 1c levels. Diabetes Res Clin Pract. 2007;77(2):280-285.
23. 1c. Diabetes Care. 2003;26(3):881-885.
24. Burgers JS, Bailey JV, Klazinga NS, Van Der Bij AK, Grol R, Feder G. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care. 2002;25(11):1933-1939.
25. Brunton S. Implementing treatment guidelines for type 2 diabetes in primary care. Postgrad Med. 2009;121(2):125-138.
26. Chacra AR, Tan GH, Apanovitch S, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Chin Pract. 2009;63(9):1395-1406.
27. Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy. 2004;24:606-620.
28. International Diabetes Federation. Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation, 2005. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed October 26, 2009.
29. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226-1232.
30. Fleck P, Mekki Q, Kipnes M, Wilson C, Pratley R. Efficacy and safety of alogliptin and glyhuride combination therapy in patients with type 2 diabetes. Abstract 76. Diabetologia. 2008;51(suppl 1):S1-S588.
31. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
32. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2008.
33. DeFronzo R, Hissa MN, Garber AJ, et al. Once daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D. Diabetes. 2009;58(suppl 1).
34. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569-583.
35. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194 205.
36. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res. 2009;41(12):905-909.
37. 1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med. 2007;24:955-961.
38. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy, Diabetes Obes Metab. 2009;11(2):157-166.
39. Goke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892-895.
40. Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11(6):589-595.
41. Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(6):571-578.
42. International Diabetes Federation. The Economics of Diabetes: Human and Social Effects. http://www.worlddiabetesday.org/files/docs/Economicaspects.pdf. 2006. Accessed December 3, 2009.
43. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187-192.